UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Blood, ISSN 0006-4971, 08/2012, Volume 120, Issue 8, pp. 1589 - 1596
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Immunopathology | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Immunoglobulinopathies | Medical sciences | Immunodeficiencies. Immunoglobulinopathies | Boronic Acids - toxicity | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Dexamethasone - toxicity | Induction Chemotherapy | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Antineoplastic Agents - toxicity | Multiple Myeloma - therapy | Pyrazines - toxicity | Antineoplastic Agents - adverse effects | Female | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Thalidomide - administration & dosage | Thalidomide - toxicity | Antineoplastic Combined Chemotherapy Protocols - toxicity | Disease-Free Survival | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Stem Cells - drug effects | Stem Cells - pathology | Aged | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Journal of medicinal chemistry, ISSN 0022-2623, 09/2016, Volume 59, Issue 17, pp. 7773 - 7782
Neoplasm Transplantation | Pyrimidines - chemical synthesis | Allosteric Regulation | Antineoplastic Agents - chemical synthesis | Humans | Crystallography, X-Ray | Male | Structure-Activity Relationship | Pyrimidines - chemistry | Heterografts | Piperidines - pharmacology | Drug Design | Female | Piperidines - pharmacokinetics | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Piperidines - chemistry | Administration, Oral | Mice, Inbred C57BL | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - antagonists & inhibitors | Models, Molecular | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - chemistry | Pyrimidines - pharmacology | Antineoplastic Agents - chemistry | Piperidines - chemical synthesis | Pyrazines - chemical synthesis | Pyrazines - chemistry | Animals | High-Throughput Screening Assays | Mice, Nude | Pyrazines - pharmacokinetics | Allosteric Site | Cell Line, Tumor | Pyrimidines - pharmacokinetics | Protein Conformation | Pyrazines - pharmacology | Index Medicus | inhibitors | INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CHEMISTRY | amines | inhibition | conformation | peptides and proteins | 60 APPLIED LIFE SCIENCES
Journal Article
Russian journal of organic chemistry, ISSN 1070-4280, 02/2020, Volume 56, Issue 2, pp. 225 - 233
Journal Article
The New England journal of medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 3, pp. 232 - 242
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Glycated Hemoglobin A - analysis | Hypoglycemic Agents - therapeutic use | Triazoles - adverse effects | Double-Blind Method | Follow-Up Studies | Administration, Oral | Humans | Kaplan-Meier Estimate | Hospitalization - statistics & numerical data | Pyrazines - therapeutic use | Cardiovascular Diseases - complications | Diabetes Mellitus, Type 2 - blood | Heart Diseases - etiology | Heart Diseases - epidemiology | Pyrazines - adverse effects | Cardiovascular Diseases - mortality | Sitagliptin Phosphate | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Heart Failure - etiology | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Triazoles - therapeutic use | Type 2 diabetes | Care and treatment | Usage | Clinical trials | Influence | Sitagliptin | Dosage and administration | Cardiovascular diseases | Myocardial infarction | Cerebral infarction | Stroke | Inhibitor drugs | Peptidase | Diabetes mellitus | Pancreatitis | Cardiovascular disease | Angina | Side effects | Pancreatic cancer | Hemoglobin | Diabetes | Health risk assessment | Drug therapy | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 26, pp. 2522 - 2533
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hypertension, Pulmonary - mortality | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Kaplan-Meier Estimate | Hospitalization - statistics & numerical data | Male | Pyrazines - therapeutic use | Disease Progression | Prodrugs - adverse effects | Acetamides - therapeutic use | Pyrazines - adverse effects | Acetamides - adverse effects | Female | Aged | Hypertension, Pulmonary - drug therapy | Prodrugs - therapeutic use | Hypertension, Pulmonary - complications | Clinical trials | Usage | Drug therapy | Pulmonary hypertension | Hypertension | Headache | Jaw | Endothelin | Pulmonary arteries | Diarrhea | Nausea | Prostacyclin | Patients | Pain | Circulatory system | Phosphodiesterase | Fees & charges | Substance abuse treatment | Statistical analysis | Committees | Drug dosages | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Drugs (New York, N.Y.), ISSN 0012-6667, 2014, Volume 74, Issue 2, pp. 223 - 242
Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology | Triazoles - administration & dosage | Triazoles - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Pyrazines - administration & dosage | Pyrazines - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Triazoles - pharmacology | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Triazoles - pharmacokinetics | Sitagliptin Phosphate | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Pyrazines - pharmacology | Drug Combinations | Triazoles - therapeutic use
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 8, pp. 1061 - 1075
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Recurrence | Aniline Compounds - pharmacology | Aniline Compounds - blood | Humans | Middle Aged | Blood Platelets | Male | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | fms-Like Tyrosine Kinase 3 - metabolism | fms-Like Tyrosine Kinase 3 - genetics | Retreatment | Maximum Tolerated Dose | Antineoplastic Agents - blood | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Antineoplastic Agents - pharmacology | Aniline Compounds - therapeutic use | Phosphorylation - drug effects | Pyrazines - pharmacology | Pyrazines - blood | Leukemia, Myeloid, Acute - genetics | Relapse | Diseases | Analysis | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article